BTL-101

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameBTL-101
Drug Alias NameBTL-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain modulatorsTumor-associated antigen modulatorsAnti-BCMA +[4] 
TargetsT-cell surface glycoprotein CD3 epsilon chainTumor-associated antigenB-cell maturation protein +[4] 
Therapy Area/IndicationsAutoimmune DiseasesMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBendao Biotechnology (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBendao Biotechnology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A